Evaluation and Management of Bleeding in Perimenopausal Women
Mentor: Sireesha Reddy
Editor: Daniel M. Breitkopf
The perimenopause is defined as the onset of intermenstrual cycle variability (±7 days) through two years after the final menstrual period. Menopause is achieved after 12 completed months of amenorrhea. During the menopausal transition, menstrual cycle inconsistencies are a reflection of the decreasing number of ovarian follicles and the resulting variability of hormone secretion and oligovulation.
Abnormal Uterine Bleeding in perimenopausal women is generally caused by AUB-O (ovulatory dysfunction). In early perimenopause, elevated FSH levels lead to the development of multiple follicles. Pregnancy is still possible, as a small portion of cycles may still be ovulatory. Endometrial hyperplasia should be considered in perimenopausal women with prolonged heavy bleeding or with risk factors such as obesity, family history, hypertension, and nulliparity.
Evaluation begins with performing a focused history on menstrual patterns, vasomotor symptoms, and genitourinary syndrome of menopause (GSM). Physical examination should evaluate for location of bleeding, assessment for structural causes, and GSM. A pregnancy test should be performed. Evaluation for structural causes of AUB, such as endometrial polyps, adenomyosis, and leiomyomas should be performed in women with persistent, heavy, or otherwise unexplained bleeding. Structural evaluation of the uterus may include transvaginal ultrasound, sonohysterography, or hysteroscopy. AUB can be a sign of endometrial hyperplasia or cancer, so women over 45 with suspected anovulatory bleeding should have an endometrial biopsy, and if non-diagnostic, hysteroscopy with sampling.
Women over 45 with typical vasomotor symptoms of menopause and increasing length between bleeding and without intermenstrual bleeding should be offered anticipatory counseling on the menopause transition. No further hormonal testing is necessary, as changes in menstrual bleeding patterns are a better predictor of menopause than hormonal assays. Early follicular FSH levels can fluctuate, from menopausal levels of 25 IU/L, to normal reproductive levels. Because of the variability in FSH levels, it should not be used in the evaluation of the perimenopausal patient.
Several medical management modalities for AUB have added benefits of pregnancy prevention, control of vasomotor symptoms, and treatment of heavy vaginal bleeding associated with AUB-O. The levonorgestrel IUD is an excellent option for the menopausal transition, protecting the endometrium, decreasing menstrual blood loss, and offering highly effective contraception. Low dose combined oral contraceptive pills have these benefits while also relieving vasomotor symptoms and GSM. Both treatment options can be continued long term based on the patient’s symptoms and need for further hormone therapy. Cyclic oral progestin and cyclic combined hormone therapy are also options for cycle control and endometrial protection. However, progestin only therapy does not treat vasomotor symptoms and neither of these options prevents pregnancy.
Acute heavy vaginal bleeding is a common problem in perimenopausal women. The most likely etiology is irregular and incomplete shedding of proliferative endometrium as a result of anovulation. Effective medical management includes use of high dose progestins, high dose estrogen, a combination oral contraceptive taper regimen, or tranexamic acid. When medical management fails, acute bleeding may be controlled with curettage or balloon tamponade.
Committee on Practice Bulletins—Gynecology. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013 Jul;122(1):176-85. doi: 10.1097/01.AOG.0000431815.52679.bb.
North American Menopause Society. (2014). Menopause Practice: A Clinician’s Guide (5th edition).
Soules MF, Sherman S, Parott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Park City, Utah, July 2001. Menopause, 2001;8:402-7.
Initial Approval September 2018, Published November 2018
********** Notice Regarding Use ************
The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.
This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.
Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.
Copyright 2018 The Foundation for Exxcellence in Women's Health, Inc. All rights reserved. No re-print, duplication or posting allowed without prior written consent.
Back to Search Results